BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 38138551)

  • 1. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
    Ryguła I; Pikiewicz W; Kaminiów K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
    Muddebihal A; Khurana A; Sardana K
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK/STAT pathway modulation: Does it work in dermatology?
    Gündüz Ö
    Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
    Niu C; Xie H; Aisa HA
    Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?].
    von Martial S; Tsianakas A
    Dermatologie (Heidelb); 2024 Mar; 75(3):256-267. PubMed ID: 38100043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
    Aihie O; Dyer JA
    Mo Med; 2023; 120(1):45-48. PubMed ID: 36860609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
    Chapman S; Kwa M; Gold LS; Lim HW
    J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK inhibitor: Introduction.
    Raychaudhuri SP; Raychaudhuri SK
    Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
    Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
    Dogra S; Sharma A; Mehta H; Sarkar R
    Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.